C12N 2760/18111
Avulavirus
Official title: Avulavirus, e.g. Newcastle disease virus
C12N2760/18111 (Avulavirus) appears on 301 US grants and 318 published applications in this corpus.
Search patents in C12N- Granted patents
- 301
- Published applications
- 318
- Assignees
- 161
- Inventors
- 616
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 2 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 6 | 0 |
| 1993 | 5 | 0 |
| 1994 | 5 | 0 |
| 1995 | 4 | 0 |
| 1996 | 6 | 0 |
| 1997 | 4 | 0 |
| 1998 | 16 | 0 |
| 1999 | 11 | 0 |
| 2000 | 17 | 0 |
| 2001 | 13 | 0 |
| 2002 | 9 | 4 |
| 2003 | 8 | 13 |
| 2004 | 7 | 14 |
| 2005 | 5 | 8 |
| 2006 | 8 | 6 |
| 2007 | 5 | 12 |
| 2008 | 4 | 10 |
| 2009 | 9 | 18 |
| 2010 | 7 | 21 |
| 2011 | 11 | 14 |
| 2012 | 4 | 11 |
| 2013 | 4 | 6 |
| 2014 | 5 | 24 |
| 2015 | 13 | 7 |
| 2016 | 14 | 16 |
| 2017 | 11 | 11 |
| 2018 | 8 | 15 |
| 2019 | 20 | 11 |
| 2020 | 5 | 13 |
| 2021 | 7 | 17 |
| 2022 | 14 | 20 |
| 2023 | 3 | 15 |
| 2024 | 9 | 11 |
| 2025 | 10 | 18 |
| 2026 | 5 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18134Use of virus or viral component as vaccineIndexing code160
- C12N 2760/18122New viral proteins or individual genes, new structural or functional aspects ofIndexing code153
- C12N 2760/18141Use of virus, viral particle or viral elements as a vectorIndexing code46
- C12N 2760/18171Demonstrated in vivo effectIndexing code28
- C12N 2760/18132Use of virus as therapeutic agent, other than vaccineIndexing code26
- C12N 2760/18151Methods of production or purification of viral materialIndexing code23
- C12N 2760/18121Viruses as suchIndexing code22
- C12N 2760/18161Methods of inactivation or attenuationIndexing code10
Recent patents
- Preparation method and application of vesicle formed by erythrocyte membrane encapsulating Newcastle disease virus30 Jun 2026US 12,668,783 B2
- Use of beta-glucan extract in the immunopotentiation of an avian animal28 Apr 2026US 12,611,420 B2Lesaffre Et Compagnie
- Recombinant vaccine against COVID-19 based on a paramyxovirus viral vector28 Apr 2026US 12,611,454 B2Icahn School of Medicine at Mount Sinai
- Multivalent HVT vector vaccine31 Mar 2026US 12,589,147 B2Intervet Inc.
- Recombinant herpesvirus of turkeys (HVT) and preparation method and use thereof6 Jan 2026US 12,516,353 B2Yangzhou University
- Apmv and uses thereof for the treatment of cancer30 Jul 2026US 2026/0216266 A1Icahn School of Medicine at Mount Sinai
- Virus attenuation30 Apr 2026US 2026/0115273 A1University of Lancaster
- Newcastle Disease Virus with Improved Heat Resistance, and Newcastle Disease Virus Vaccine Comprising Same5 Mar 2026US 2026/0061047 A1Biopoa, Inc.
- Recombinant vaccine against covid-19 to produce cellular response in individuals with pre-existing immunity11 Dec 2025US 2025/0375515 A1Consejo Nacional De Humanidades, Ciencias Y TecnologíAS
- Fusosome compositions and uses thereof4 Dec 2025US 2025/0369018 A1Flagship Pioneering Innovations V, Inc.
Most cited
By later US patents
- Recombinant new castle disease virus RNA expression systems and vaccines164US 6,146,642 AMount Sinai School of Medicine of the City University of New York · 2000
- Recombinant avipox virus and immunological use thereof151US 5,174,993 AHealth Research, Inc. · 1992
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Process for the production of virus vaccine116US 4,659,569 AKabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo · 1987